The combination of SRA737, an oral CHK1 inhibitor, with or without anti–PD-L1/anti-PD-1 leads to an antitumor response in multiple cancer models, including Small Cells Lung Cancer (SCLC). This evidence concerns the gene CD274 and small cell lung carcinoma.